New combo therapy aims to slow advanced liver cancer

This study tests two different ways to give chemotherapy combined with immunotherapy and a targeted drug for people with advanced liver cancer (BCLC stage C). One group gets standard IV chemo plus the drugs camrelizumab and apatinib. The other group gets the same drugs but with chemo delivered directly to the liver through a catheter (HAIC). The goal is to see which approach better controls the cancer and protects liver function. About 262 adults aged 18-75 with good liver function who haven't had prior systemic therapy will participate.